Cover Image
市場調查報告書

中國的Trastuzumab市場調查

Investigation Report on China Trastuzumab Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 296113
出版日期 內容資訊 英文 20 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的Trastuzumab市場調查 Investigation Report on China Trastuzumab Market, 2010-2019
出版日期: 2015年06月18日 內容資訊: 英文 20 Pages
簡介

Trastuzumab是妨礙HER2/neu受體的單株抗體,主要是用作特定乳癌的治療。Trastuzumab在治療HER2陽性轉移性乳癌上有莫大影響。中國由於醫療環境的限制及知識不足,每年接受乳腺疾病檢查的女性為10%以下。為此,初期階段發現的乳癌,美國是80%,但中國僅為20%。在中國的醫院市場中,Shanghai Roche 與GENENTECHT佔Trastuzumab的市場佔有率。在2005-2014年之間,醫院的Trastuzumab的市場規模年複合成長率達到52.9%。

本報告提供中國的Trastuzumab市場相關分析,提供您提供您主要廠商的市場佔有率,中國的醫院市場上價格變化·銷售額,主要企業,及市場展望等資訊。

第1章 Trastuzumab的相關概念

  • 適應症
  • 全球市場的銷售情形

第2章 中國的Trastuzumab的市場概要

  • 專利情形
  • 主要製造商
  • 市場規模

第3章 中國的Trastuzumab的銷售額調查

  • 銷售額
    • 整體銷售額
    • 各地區
  • 銷售額
    • 總銷售額
    • 各地區

第4章 中國的主要Trastuzumab製造商市場佔有率調查

  • 市場佔有率:各銷售額
  • 市場佔有率:不同銷售額

第5章 Trastuzumab的市場規模調查:中國的不同投藥形態

  • 市場佔有率:銷售額·不同投藥形態
  • 市場佔有率:銷售額·不同投藥形態

第6章 中國的醫院市場上Trastuzumab的標準價格

  • GENENTECH (商標名: Herceptin)的Trastuzumab產品
  • Shanghai Roche (商標名: Herceptin)的Trastuzumab產品

第7章 中國的主要Trastuzumab製造商分析

  • Shanghai Roche Pharmaceuticals Ltd.
  • GENENTECH (美)

第8章 中國的Trastuzumab市場展望

  • 市場規模預測
  • 競爭格局預測

主要表(圖表)

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1506217

Monoclonal antibody, an epochal drug variety, plays an important role in the upgrading process of treatments for tumor and autoimmune disease, and has become a mainstream in the global market of targeting therapeutic agents. The manufacturers of antibody mainly concentrate in the hands of such drug giants as Roche, Amgen, Johnson & Johnson, Abbott, Novartis and Merck, among which Roche's Genetech boasts of the largest amount of monoclonal antibody varieties.

Developed by Genentech, trastuzumab was approved by FDA to be used in clinic in Sep. 1998 under the trade name of Herceptin, a major product of Roche. In 2013, the sales value of trastuzumab was USD 6.56 billion around the world.

After entering China in 2002 for the treatment of HER2 metastatic breast cancer, trastuzumab develops fast with annual sales value rising from less than CNY 20 million in 2005 to CNY 577 million in 2014 and CAGR during this period reaching up to 52.9%. Currently, trastuzumab in the Chinese market are monopolized by the subsidiary companies of Roche such as Genentech and Shanghai Roche Pharmaceutical Co., Ltd who has the largest market share of 80.60% with sales value in 2014 reaching up to CNY 465 million.

Due to its low toxicity and obvious therapeutic effects, trastuzumab can prolong patients' lives and improve the life quality of patients with advanced cancer, thus becoming the major driving force behind the growth of tumor monoclonal antibody market. The market size of trastuzumab in China is expected to keep expanding in the next few years.

Readers can get at least the following information from this report:

  • market size of trastuzumab in China
  • price of trastuzumab in Chinese market
  • major manufacturers of trastuzumab in Chinese market
  • market outlook of trastuzumab in China

The author suggests the following groups of people purchase this report:

  • manufacturers of monoclonal antibody
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Trastuzumab

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Trastuzumab in China

  • 2.1. Patent and Approval Status of Trastuzumab in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Trastuzumab in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Trastuzumab in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Trastuzumab in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Trastuzumab in Chinese Hospitals in 2014

  • 6.1. GENENTECH(US) (Trade Name: Herceptin)
  • 6.2. Shanghai Roche Pharmaceutical Co., Ltd (Trade Name: Herceptin)

7. Major Manufacturers of Trastuzumab in Chinese Market, 2010-2014

  • 7.1. Shanghai Roche Pharmaceutical Co., Ltd
  • 7.2. GENENTECH (US)

8. Market Outlook of Trastuzumab in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Sales Status of Trastuzumab in China
  • Chart Sales Value of Trastuzumab in China, 2010-2014
  • Chart Sales Value of Trastuzumab in Some Regions in China, 2010-2014
  • Chart Sales Volume of Trastuzumab in China, 2010-2014
  • Chart Sales Volume of Trastuzumab in Some Regions in China, 2010-2014
  • Chart Market Share of TOP2 Manufacturers of Trastuzumab for Sales Value in China, 2010-201
  • Chart Sales Value and Market Share of Trastuzumab Made by Shanghai Roche in China, 2010-2014
  • Chart Sales Value and Market Share of Trastuzumab Made by GENENTECH(US) in China, 2010-2014
  • Chart Sales Value and Market Share of Trastuzumab Injection in China, 2010-2014
  • Chart Sales Volume and Market Share of Trastuzumab Injection in China, 2010-2014
  • Chart Price of Trastuzumab Made by GENENTECH(US) in Some Chinese Cities in 2014
  • Chart Price of Trastuzumab Made by Shanghai Roche Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Back to Top